|
ARL17A expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62647673107585E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.43920431128208E-11 |
| Normal-vs-Stage2 |
2.41519999555351E-08 |
| Normal-vs-Stage3 |
1.23900889548167E-13 |
| Normal-vs-Stage4 |
3.87301302140486E-12 |
| Stage1-vs-Stage2 |
9.483800E-01 |
| Stage1-vs-Stage3 |
8.263500E-02 |
| Stage1-vs-Stage4 |
4.416500E-02 |
| Stage2-vs-Stage3 |
2.250000E-01 |
| Stage2-vs-Stage4 |
7.963600E-02 |
| Stage3-vs-Stage4 |
4.840200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
6.32827124036339E-15 |
| Normal-vs-AfricanAmerican |
5.96400040464573E-10 |
| Normal-vs-Asian |
1.48740000005532E-06 |
| Caucasian-vs-AfricanAmerican |
4.260100E-02 |
| Caucasian-vs-Asian |
1.885350E-01 |
| AfricanAmerican-vs-Asian |
2.120500E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.1094237467878E-15 |
| Normal-vs-Female |
1.93389748659456E-12 |
| Male-vs-Female |
2.861600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.7625900738949E-12 |
| Normal-vs-Age(41-60Yrs) |
1.51969992145951E-10 |
| Normal-vs-Age(61-80Yrs) |
1.75615078035207E-12 |
| Normal-vs-Age(81-100Yrs) |
1.99559999636278E-08 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.872800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.594000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.590300E-02 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.244800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.600400E-02 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
1.644590E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
4.399500E-03 |
| Classical-VS-Follicular |
9.555900E-02 |
| Classical-VS-Other |
5.171400E-01 |
| Classical-VS-Normal |
1.64779301314866E-12 |
| Tall-VS-Follicular |
4.587000E-04 |
| Tall-VS-Other |
5.408600E-01 |
| Tall-VS-Normal |
9.2148511043888E-14 |
| Follicular-VS-Other |
6.559500E-02 |
| Follicular-VS-Normal |
1.80589999954073E-07 |
| Other-VS-Normal |
2.408000E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.09479092458287E-12 |
| Normal-vs-N1 |
3.5141999999988E-05 |
| N0-vs-N1 |
9.906000E-01 |
|
|
